Surfing the MASH Tsunami

Send us Fan Mail SurfingNASH invited four attendees to the NASH-TAG wrap up (three first-timers, two corporate executives) to focus on presentations and discussion from the fireside chats. Highlights include: 4:20 – Introduction of first-time panelists Amy Articolo (Novo Nordisk), Erin Quirk (Terns Pharmaceuticals), Rachel Zayas (AGED Diagnostics) and the returning Ian Rowe (University of Leeds) 1...

Send us Fan Mail SurfingNASH is covering each day of NASH-TAG 2022. This episode is a "morning after" conversation with Stephen Harrison, Louise Campbell and Jörn Schattenberg reviewing key points of the Day Two discussions, with particular focus on the two "fireside chats" that wrapped up the program. Day Two of NASH-TAG included presentations of new data on wet markers, imagi...

Send us Fan Mail SurfingNASH is covering each day of NASH-TAG 2022. This episode includes two separate conversations, with Stephen Harrison, Louise Campbell, Mazen Noureddin and Quentin Anstee in the first and Donna Cryer and Scott Friedman in the second. Several common themes emerged in the two conversations, including the ideas that the future of NASH therapy lies in combination therapies and ho...

Send us Fan Mail In advance of NASH-TAG 2022 this weekend, Jörn Schattenberg joins the Surfers to answer a key conference question: are we ready to pivot toward non-invasive tests and better uses of histopathology? The group explores a range of questions and ideas that are likely to emerge during Saturday night's fireside chats. The group explores a range of questions and ideas that are likel...

Send us Fan Mail This conversation is part of SurfingNASH's 2021 NAFLD Year-In-Review. Andrew Scott, Global Policy Lead for the Global Liver Institute joins Louise Campbell and Roger Green to discuss the growing energy and impact of NASH patient advocacy. This episode focuses on the steps that have increased reach and effectiveness of NASH patient advocacy dramatically in 2021. Andrew starts...

Send us Fan Mail This conversation is part of SurfingNASH's 2021 NAFLD Year-In-Review. Professor Jeffrey Lazarus of ISGlobal and the University of Barcelona joins Louise Campbell and Roger Green to discuss the emerging NAFLD public health agenda. Jeff Lazarus comes to the effort to create a global NAFLD Public Health agenda from his experiences spearheading similar efforts in HIV and Hepatiti...

Send us Fan Mail This conversation is part of SurfingNASH's 2021 NAFLD Year-In-Review. Co-host Dr. Stephen Harrison joins Louise Campbell and Roger Green to review five key NASH themes that emerged in 2021, while simultaneously discussing the year for Surfing the NASH Tsunami. It seems fitting that the first SurfingNASH event of 2022 should include Stephen, Louise and Roger. In this thoughtfu...

Send us Fan Mail The last half of December marks our annual NAFLD Year-in-Review. Episodes 62-64 each include ~20 minute segments of longer interviews with Stakeholders who have made a dent in Fatty Liver disease in 2021. In this episode, Louise Campbell and Roger Green are joined by Stephen Harrison, Jeff Lazarus and Andrew Scott. Conversation topics vary widely, with Stephen describing on what h...

Send us Fan Mail This conversation is part of SurfingNASH's 2021 NAFLD Year-In-Review. Professor Jörn Schattenberg of the University of Mainz joins Louise Campbell and Roger Green to discuss research and insights regarding NASH cost effectiveness studies and related issues of quality of life. Jörn Schattenberg begins our discussion simply by reviewing some of the year's highlights. His &...

Send us Fan Mail This conversation is part of SurfingNASH's 2021 NAFLD Year-In-Review. Professor Kenneth Cusi of the University of Florida joins Louise Campbell and Roger Green to discuss the NASH multidisciplinary initiative organized under the aegis of AGA the resulting paper of Clinical Care Pathways. In 2021, Ken Cusi played an integral role in the NASH Multidisciplinary initiative foster...

Send us Fan Mail This conversation is part of SurfingNASH's 2021 NAFLD Year-In-Review. Professor Manal Abdelmalek of Duke University joins Louise Campbell and Roger Green to discuss the use of older drugs to treat cirrhosis patients today and her views on where NASH drug development is heading. Manal begins by discussing the inherent tension between the research world, which reveals several p...

Send us Fan Mail The last half of December marks our annual NAFLD Year-in-Review. Episodes 62-64 each include ~20 minute segments of longer interviews with Stakeholders who have made a dent in Fatty Liver disease in 2021. In this episode, Louise Campbell and Roger Green are joined by Manal Abdelmalek, Kenneth Cusi and Jörn Schattenberg. Highlights: 3:26 – Manal Abdelmalek introduction and discussi...

Send us Fan Mail This conversation is part of SurfingNASH's 2021 NAFLD Year-In-Review. Fatty Liver Foundation Founder and President Wayne Eskridge joins Louise Campbell and Roger Green to discuss the recently-completed SUNN study that was initiated and shepherded by FLF. Wayne discusses study results and the challenges for an orgganization like FLF in conducting this kind of study.  Wayne foc...

Send us Fan Mail This conversation is part of SurfingNASH's 2021 NAFLD Year-In-Review. Professor Alina Allen of the Mayo Clinic joins Louise Campbell and Roger Green to discuss the rapid progress the profession has made in improving user-friendliness and ease of interpretation of MRE and the coming expansion in the role that non-invasive liver testing will play in the years to come. Alina not...

Send us Fan Mail This conversation is part of SurfingNASH's 2021 NAFLD Year-In-Review. Dr. Mazen Noureddin, Director of the Fatty Liver Program at Cedars Sinai, Los Angeles, joins Louise Campbell and Roger Green to discuss advances in AI in histopathology. Mazen Noureddin notes that while non-invasive tests are important and likely to become more so over time, drug development today will need...

Send us Fan Mail The last half of December marks our annual NAFLD Year-in-Review. Episodes 62-64 each include ~20 minute segments of longer interviews with Stakeholders who have made a dent in Fatty Liver disease in 2021. In this episode, Louise Campbell and Roger Green are joined by Mazen Noureddin,  Alina Allen, Wayne Eskridge. Highlights:  7:51 – Mazen Noureddin begins talking about AI and hist...

Send us Fan Mail SPLENDOR lead author Ali Amirian, the Surfers and audience member Shardool Jain of Altrix Bio debate whether and when bariatric surgery might become first line therapy for multi-morbid metabolic patients.  Dr. Jain takes the position that for many patients with metabolic co-morbidities, drugs tends not to work over time, so why not go to bariatric earlier in therapy...even in firs...

Send us Fan Mail A question from Ali Aminian leads the group to ponder whether cirrhosis can truly be regressed. The consensus is that many good things can happen (for example, fibrosis can be regressed) but that platelet levels never rebound. From there, the panel considers the likely effect of the later-generation GLP-1s like semaglutide or tirzepatide, which report 10-15% overall weight loss, o...

Send us Fan Mail The Surfers, joined by SPLENDOR lead author Ali Aminian, broaden their discussion into considering MACE and MALO patients into clinical trials. After Roger Green notes that the percentage reductions in MACE (7.2%) and MALO (7.3%) were virtually identical, the group returns to explore the question of including co-morbid metabolic patients in clinical trials. To spur the discussion...

Send us Fan Mail Lead author Ali Aminian shares key findings from SPLENDOR on the impact of bariatric surgery on Major Adverse Cardiovascular Events (MACE) and Major Adverse Liver Outcomes (MALO). Top-line: over a ten-year followup period, bariatric surgery led to a fourfold decrease in MALO and almost a twofold decrease in MACE. This led Stephen Harrison to ask whether it makes sense to combine M...

Send us Fan Mail Lead author Dr. Ali Aminian of the Cleveland Clinic joins the Surfers to discuss the recent SPLENDOR Study, which focuses on the effects of bariatric surgery on Major Adverse Cardiovascular Events (MACE) and Major Adverse Liver Outcomes (MALO).  Stephen Harrison and Roger Green are joined by Fatty Liver Foundation President Wayne Eskridge. 9:02 - Ali Aminian begins to discuss the...

Send us Fan Mail NASH-TAG 2022 takes place in Deer Valley Utah and on-line from January 7-8, 2022. Join Surfing NASH to learn about the last three sessions of the meeting, which include multi-stakeholder "fireside chats" about how to make progress in non-invasive testing for non-cirrhotic NASH and NASH cirrhosis. Co-chair Stephen Harrison leads the panel through key sessions from NASH-TA...

Send us Fan Mail NASH-TAG 2022 takes place in Deer Valley Utah and on-line from January 7-8, 2022. Join Surfing NASH to learn about important updates from the three consortia (LITMUS, NIMBLE and the NIH Cirrhosis Network), "new news" in wet biomarkers and combination therapy and a stimulating session with PathAI and Histoindex covering artificial intelligence. Co-chair Stephen Harrison l...

Send us Fan Mail NASH-TAG 2022 takes place in Deer Valley Utah and on-line from January 7-8, 2022. Join Surfing NASH to learn about the important and innovative drug development and basic science talks in the meeting. Co-chair Stephen Harrison leads the panel through each of the sessions during the conference's first morning. The session starts with Michael Charlton's annual "Year i...

Send us Fan Mail NASH-TAG 2022 Co-chair Stephen Harrison and Steering Committee Member Jörn Schattenberg review the upcoming conference, focusing on major issues in NAFLD and NASH diagnosis, staging, treatment and monitoring. NASH-TAG 2022 faculty, format and schedule suggest that this conference will produce breakthroughs in knowledge and consensus about NAFLD therapy. This week, NASH-TAG 2022 St...